Disease Control

India’s short supply of basic antibiotics is making its drug resistance problem worse

Some essential antibiotics are under price control and drug manufacturers are less inclined to make them.

India is witnessing an alarming rise in antibiotic resistance, much of which has been triggered by overprescription of the drugs by doctors, overuse by patients and unregulated use on farms and fisheries. But another factor contributing to this rise in antibiotic resistance is the unavailability of simple antibiotics that should be used as the first line of treatment.

The lack of such first line antibiotics has resulted in people across India using stronger drugs to treat simple infections. Pathogens, therefore, develop resistance to these stronger drugs faster and render even the more basic antibiotics ineffective.

On June 6, the World Health Organisation updated its Essential Medicines List, revising the antibiotic section extensively. Keeping in mind extensive and growing antibiotic resistance across the world, the WHO grouped antibiotics into three categories – access, watch and reserve with recommendations on when each drug can be used.

The “access” category has 29 first-generation antibiotics that should be widely available and affordable, states the WHO document. The “watch” group of antibiotics can be the first and second choice for treatment of a small set of infections but whose use should be reduced as much as possible to prevent resistance. “Reserve” antibiotics are last resort medicines to be only in the most severe circumstances when all other alternatives have failed.

In India, many of the “access” group antibiotics are only sparsely available.

“Antibiotics such as benzathine penicillin, ampicillin and nitrofurantoin are not available in the country,” said Dr Sumanth Gandhra from Centre for Disease Dynamics, Economics and Policy, a public health research organisation with its headquarters in Washington DC. “At least not as much as they are supposed to be.”

Gandhra, who works at the centre’s Delhi office, was an advisor to the WHO committee that updated the Essential Medicines List.

Benzathine penicillin injections are commonly used for treating syphilis and rheumatic heart disease in children. Ampicillin is used to treat a variety of bacterial infections and nitrofurantoin is used to treat urinary tract infections.

Many of these “access” category antibiotics are narrow spectrum drugs that target certain kinds of bacteria and do not attack the beneficial bacteria that are generally found in the human body. Stronger antibiotics are broad spectrum drugs that are more effective. But continued and widespread use of these stronger antibiotic makes pathogens resistant to them faster and also resistant to the less potent, basic drugs. The basic drugs then fail to kill the new drug-resistant pathogens. Therefore, the availability of “access” category drugs is important to control the spread of antibiotic resistance.

At the same time, there are a few cases in which drugs that had been rendered ineffective decades ago due to resistance seem to be working in the Indian population again. In the 1980s, there were many cases of multi-drug resistant typhoid, which led to the reduced use of ampicillin that was used to treat the disease. Now, samples of the Salmonella typhi bacteria are showing sensitivity to ampicillin again.

Color-enhanced scanning electron micrograph showing Salmonella Typhimurium (red) invading cultured human cells. (Image: Rocky Mountain Laboratories, NIAID, NIH/Wikimedia Commons)
Color-enhanced scanning electron micrograph showing Salmonella Typhimurium (red) invading cultured human cells. (Image: Rocky Mountain Laboratories, NIAID, NIH/Wikimedia Commons)

Dr Yogesh Jain, one of the founders of the Jan Swasthya Sahyog and who runs the community hospital in Bilaspur, Chattisgarh, said only certain pharmaceutical distributors stock first line antibiotics and other essential medicines.

“Sometimes these drugs are more often available in Chhattisgarh than in Delhi,” said Jain.

First line antibiotics are also more easily available in government run facilities than in private pharmacies, clinics and hospitals. This is because these drugs are part of the National Essential Medicines List that is used to procure medicines in the public sector.

Dr Mukesh Agarwal, head of pediatrics at KEM Hospital in Mumbai said that the municipal teaching hospital is able to procure drugs like benzathine penicillin even though it is difficult to find in private facilities.

Benzathine penicillin is given as an injection once every 21 days to children suffering from rheumatic heart disease. Another option to treat the disease is with the an oral pill of erythromycin, which is the less preferred mode of treatment.

“The chances of defaulting on taking the medication is higher when the doctors prescribe the pill,” said Agarwal.

Even public hospitals that have better supply of first line antibiotics do not get as much of these medicines as required. Shortages sometimes compel pharmacists to give patients have the amount of medicine required for a five-day course and ask them to collect the remaining medicines after two days.

“The patient starts feeling better after two days of taking medicines,” said Dr Anita Kotwani, professor at the department of Pharmacology at VP Chest Institute in Delhi. “Will he come back to collect the rest of his dose? No. This suboptimal dose kills only half the bacteria in the body. The other half become resistant.”

Some antibiotics like doxycycline are easily available in combinations but not as single molecule formulations. “Combination drugs are more likely to cause drug resistance,” said Kotwani.

The price control factor

Kotwani has conducted several surveys on the availability and affordability of essential medicines. In 2013, just before the government released its Drug Price Control Order, she found that doxycycline was easy to find at both public and private health facilities in Delhi. In 2015, the drug, which had come under price control, was not as easily available. Drug manufacturers are less inclined to make drugs that are under price control and therefore less profitable than those for which prices are not regulated, said Jagannath Shinde, chairman of All India Organisation of Chemists and Druggists.

“After price control, companies feel that it is not affordable for them to produce the drug,” said Shinde. “They do not stop production. They just reduce the quantity of drugs they produce. Naturally, it will not be as easily available everywhere.”

The general availability or lack of antibiotics affects what medicines doctors prescribe.

“It is a vicious cycle,” said Dr Vijay Yewale, a pediatrician from Navi Mumbai and former president of Indian Academy of Pediatrics. Doctors stop prescribing antibiotics that are in short supply and, in turn, manufacturers make less of these antibiotics that doctors are no longer prescribing as much.

S Srinivasan, who runs a generic drug manufacturing company in Vadodara called LOCOST and is also part of the All-India Drug Action Network said that many of these first-generation antibiotics are “out-of-fashion”.

“Often the doctors fall prey to the marketing of the pharma companies,” said Srinivasan, about why some doctors might prescribe more advanced antibiotics.

Kotwani said that doctors also try to retain their patients with quick cures, prescribing what they call “effective” and expensive broad spectrum antibiotics instead of first line antibiotics.

Said Yewale: “There are some doctors who are not as rational in their prescription and have not upgraded themselves. If the patient is not very ill, why not try the simple narrow spectrum drugs first and check if it works?”

Support our journalism by subscribing to Scroll+ here. We welcome your comments at letters@scroll.in.
Sponsored Content BY 

The qualities of a high-performance luxury sedan

A lesson in harnessing tremendous power to deliver high performance.

Gone are the days when the rich and successful would network during a round of golf, at least in the Silicon Valley. As reported by New York Times, ‘auto-racing has become a favourite hobby for the tech elites’. However, getting together on a race track would require a machine that provides control while testing extreme limits. Enter the Mercedes-AMG range of cars.

Mercedes-AMG’s rise from a racing outfit to a manufacturer of peak performance cars is dotted with innovations that have pushed the boundaries of engineering. While the AMG series promises a smooth driving experience, its core is made up of a passion for motorsports and a spirit that can be summarized in two words – power and performance. These integral traits draw like-minded people who share and express Mercedes-AMG’s style of performance.

The cars we drive say a lot about us, it’s been said. There are several qualities of an AMG performance luxury sedan that overlap with the qualities of its distinguished owner. For instance, creating an impression comes naturally to both, so does the ambition to always deliver an exceptional performance. However, the strongest feature is that both the owner and the AMG marque continually challenge themselves in pursuit of new goals, stretching the limits of performance.

This winning quality comes alive, especially, in the latest Mercedes-AMG marque – the Mercedes-AMG E 63 S 4MATIC+. With the most powerful engine to have ever been installed in an E-class, this undisputed performance sedan promises immense power at the driver’s command. With 612 HP under its hood, the car achieves 0-100 km/h in just a few seconds - 3.4 to be precise. Moreover, the car comes with the latest driver-assistance technology that promises intelligent control and provides an agile and responsive ride.

But, the new AMG is not just about work (or traction in car lingo). One of its core features is to provide its owners a challenge on the race track. Its drift mode, which converts the vehicle into a pure rear-wheel drive, offers pure exhilaration and adds a work-play dynamic to the car. In that sense, the new AMG is a collaborator of sorts - one that partners with its owner to create an impression through performance. And on the weekends, the car pushes him/her to express absolute power using its race mode with a thunderous roar of the engine - the pure sound of adrenalin. This balance between work and play has been achieved using cutting-edge features in the car that together create an almost intuitive driver-machine relationship.

If you’re looking for a car that shares your enthusiasm for driving, you’ll find a partner in the new AMG. However, buying an AMG is not just about owning a powerhouse on wheels, it’s also about adopting a driving philosophy in which power is just the starting point - the main skill lies in how you manoeuvre that power on the road. A performance sedan in its sportiest form, Mercedes-AMG’s latest model takes vehicle performance to an unmatched level. A decade ago, this amount of speed and power in a luxury 4-door model would be un-thinkable.

Play

The new Mercedes-AMG comes with a host of individualisation options through designo, the artistic side of Mercedes’s innovation, so the car becomes an extension of the owner’s distinctive personality. An expressive design with a new radiator grille and a muscular front apron showcase its athleticism. A new-age driver environment, widescreen cockpit, the AMG performance steering wheel and sports seat delivers an intensive driving experience. With the Mercedes-AMG E 63 S 4MATIC+, AMG has created an undisputed performance sedan that can rip the race track as well as provide reliable luxury sedan-duty. To know more about the most powerful E-class of all time, see here.

This article was produced by the Scroll marketing team on behalf of Mercedes-Benz and not by the Scroll editorial team.